Search

Displaying results 1421 - 1430 of 10000 in total
  1. Drug

    Entrectinib

    go.drugbank.com/drugs/DB11986
    ApprovedInvestigational

    [L8081] It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positive solid tumors. … [L8207] Entrectinib's approved use is meant as a last line of therapy due to its accelerated approval based on early trial data.

    Synonyms: N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide
  2. Drug

    Dacarbazine

    go.drugbank.com/drugs/DB00851
    ApprovedInvestigational

    An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). … Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma.

  3. Drug

    Pentoxifylline

    go.drugbank.com/drugs/DB00806
    ApprovedInvestigational

    [A226608] Pentoxifylline has been marketed in Europe since 1972; PTX extended-release tablets sold under the trade name TRENTAL by US Pharm Holdings were first approved by the FDA on Aug 30, 1984, but … its possible use in diverse conditions, including osteoradionecrosis, diabetic kidney disease, and generally any condition associated with fibrosis.

    International brands: An Ruo NingCategories: Compounds used in a research, industrial, or household setting
  4. Drug

    TrenibotulinumtoxinE

    go.drugbank.com/drugs/DB19082
    Approved

    TrenibotulinumtoxinE is a botulinum neurotoxin serotype E, produced in *Clostridium botulinum*, used for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. … [L64118] It is the first and only rapid-onset, short-duration botulinum neurotoxin serotype E approved in Europe.[L64118]

    Synonyms: BOTULINUM NEUROTOXIN SEROTYPE E (BONT/E) (EB-001), BONTOXILYSIN-E
  5. Drug

    Omalizumab

    go.drugbank.com/drugs/DB00043
    ApprovedInvestigational

    [A39518] Omalizumab was first approved in the US in 2003 [A263507] and in Europe in 2005. … Omalizumab is a recombinant DNA-derived humanized monoclonal antibody directed against human immunoglobulin E (IgE).

    Products: XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/1.0ML, XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG/0.5ML
  6. Drug

    Edetic acid

    go.drugbank.com/drugs/DB00974
    ApprovedInvestigationalVet approved

    It is used in pharmaceutical manufacturing and as a food additive.

    Synonyms: N,N'-1,2-Ethane diylbis-(N-(carboxymethyl)glycine)Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    Etoperidone

    go.drugbank.com/drugs/DB09194
    ApprovedWithdrawn

    Etoperidone is an atypical antidepressant introduced in Europe in 1977. … It is a phenylpiperazine-substituted triazole derivative with a composition that classifies it as an analog of tradozone and presents a similar pharmacological profile.

  8. Drug

    Dasiglucagon

    go.drugbank.com/drugs/DB15226
    Approved

    [L39190] Severe hypoglycemia is an acute, life-threatening medical condition resulting from a profound drop in blood glucose levels. … [L39195] In March 2021, the FDA approved dasiglucagon to treat severe hypoglycemia in patients six years and older with diabetes. It is available as a subcutaneous injection marketed as ZEGALOGUE.

  9. Drug

    Exagamglogene autotemcel

    go.drugbank.com/drugs/DB15572
    ApprovedInvestigational

    [L10139] Following engraftment, it causes an increase in the production of HbF and a subsequent decrease in HbS. … [L49246] In January 2024, exagamglogene autotemcel received an additional FDA approval for the treatment of transfusion-dependent β-thalassemia.

  10. Drug

    Trametinib

    go.drugbank.com/drugs/DB08911
    ApprovedInvestigational

    [A258298] It was later approved by Health Canada on July 18, 2013 [L45588] and by the European Commission on June 30, 2014. … [A258298,A258293] It was first approved by the FDA in May 2013 for the treatment of melanoma.